Study highlights efficacy of La Roche-Posay’s treatment for rosacea-prone skin


- Last updated on GMT

La Roche-Posay Rosaliac AR proven to treat rosacea prone skin

Related tags Medicine

A new study conducted by La Roche-Posay Laboratoire Dermatologique has proven the efficacy of the French firm’s Intensive Care treatment in treating visible redness in patients with rosacea-prone skin.

Rosacea is a skin condition with several detrimental cosmetic effects such as skin redness, as well as pain sensations and hyper-reactivity to common triggers such as sun exposure as well as some foods and drinks; and can lead some sufferers to experience low self-esteem.

In most cases there is no specific treatment for the condition and this has seen many skin care specialists develop such products, that whilst not a prescribed drug or cure, can be bought over-the-counter.

Redness reduction

A recent study, published in the peer-reviewed Journal of Drugs in Dermatology​ has shown that La Roche Posay’s Rosaliac AR, which contains Ambophenol, Neurosensine and La Roche-Posay Thermal Spring Water, is an effective treatment due to its soothing and antioxidant properties.

"The number one goal of the Rosacea patient is to appear less red in the mirror and to the world. In addition, most rosacea-prone skin types can demonstrate a defective skin barrier that contributes to the inflammatory cascade of Rosacea, making them highly reactive to environmental factors and traditional skin treatments and moisturizers,"​ says dermatologist Dr. Neal Bhatia.

"A product like La Roche-Posay Rosaliac AR Intense Localized Redness Intensive Care that offers 24-hour hydration can help reduce visible redness and sensations of discomfort, as well as rebuild a compromised barrier and provide an immediate cooling effect to ease skin upon contact."

Testing, testing…

La Roche-Posay’s study entitled "Management of Rosacea-Prone Skin: Evaluation of a Skincare Product Containing Ambophenol, Neurosensine and La Roche-Posay Thermal Spring Water as Monotherapy or Adjunctive Therapy" explored the effect of a skin care formula housed in hermetically-sealed, patented packaging on the management of rosacea-prone skin.

It tested the formula in three different therapeutic regimes: the first and second as a monotherapy, and the third as adjunctive therapy and maintenance after a Metronidazole treatment, one of the leading topical prescriptions for rosacea.

La Roche-Posay noted that in the monotherapy regime, there was significant efficacy associated with an excellent tolerance, and when tested as maintenance treatment the formula helped prolong the efficacy of the Metronidazole drug treatment.

Related topics Formulation & Science Skin Care

Related news

Show more

Related products

Innovation Sensations: The New Roaring Twenties

Innovation Sensations: The New Roaring Twenties

Accupac | 01-Mar-2023 | Technical / White Paper

It may be difficult to envision a post-pandemic consumer market, but beauty care is poised to experience a surge of growth and innovation not seen in some...

Breaking Into Darker Skin Cosmetics

Breaking Into Darker Skin Cosmetics

Tagra Biotechnologies | 21-Feb-2023 | Product Brochure

DeeperCaps™ provide increased formula stability for cosmetic manufacturers. The innovative microencapsulation technology prevents pigment mixing and capsules...

Related suppliers

Follow us


View more